EBGene trial: patient preselection outcomes for the European GENEGRAFT ex vivo phase I/II gene therapy trial for recessive dystrophic epidermolysis bullosa

Br J Dermatol. 2020 Mar;182(3):794-797. doi: 10.1111/bjd.18559. Epub 2019 Nov 27.

S Gaucher^{1

2

3}, S M Lwin⁴, M Titeux¹, A Abdul-Wahab⁴, N Pironon^{1

2}, A Izmiryan^{1

2}, S Miskinyte¹, C Ganier¹, S Duchatelet¹, J E Mellerio⁴, E Bourrat⁵, J A McGrath⁴, A Hovnanian^{1

2

6}

¹ INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute, Paris, France.
² University Paris Descartes-Sorbonne Paris Cité, Paris, France.
³ Service de Chirurgie Générale, Plastique et Ambulatoire, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France.
⁴ St John's Institute of Dermatology, King's College London, London, U.K.
⁵ Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.
⁶ Department of Genetics, Assistance Publique-Hôpitaux de Paris, Necker Hospital for Sick Children, Paris, France.

No abstract available

Publication types